Articles On Arc Exploration (ASX:ARX)

The All Ordinaries Index (ASX: XAO) is wobbling in and out of the green on Tuesday, but its volatility hasn’t proven enough to stop five shares that call the index home from posting brand new 52-week highs. Indeed, some gained as much as 9...

Tuesday is shaping up to be rough one for many All Ordinaries Index (ASX: XAO) shares. Fortunately, though, not all companies that call the index home are suffering. Indeed, two are soaring into the green to crack new 52-week highs. Right...

Analysts at Wilsons have put the spotlight on one All Ordinaries Index (ASX: XAO) share it prefers over the Polynovo Ltd (ASX: PNV) share price. Polynovo shares fell 3.23% today to $1.98. For perspective, the All Ordinaries Index climbed...

The S&P/ASX 200 Index (ASX: XJO) has faded in afternoon trade but remains on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 6,804.5 points. Four ASX shares that are climbing more than most to...

It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements.  Several small caps from Tech and Healthcare released their reports today, showing that they’re still thriving despite...

Franklin Templeton says innovation accelerates despite recessions, pandemic, wars Expect advancements in sectors like gene therapy and augmented reality in healthcare New ways to grab our attention are reinventing the media industry Frank...

While there are many successful companies on the ASX that solely serve Australian consumers, there are huge markets to be conquered beyond the seas that girt this land. Expanding internationally is difficult to execute but the end result o...

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares leading brokers have named as buys t...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Dark clouds continue to hover over ASX health stocks Health imaging company Volpara’s FY22 results in line with expectations Fight for fertility company Virtus enters another round Healthcare and life sciences expert Scott Power – a senio...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

With COVID-19 Omicron surging around the globe, ASX healthcare shares are back in the spotlight. While most don’t deal with the pandemic directly, there are many health and biotechnology companies on the ASX that are plugging away quietly...

After a difficult 2021, the Polynovo Ltd (ASX: PNV) share price has bounced 13% this morning after the company provided a trading update. It’s the first notable public communication from the company since the resignation of its long-time se...

There aren’t too many ASX shares that can lay claim to a 10 bagger return in less than 2 years, and there are even fewer fund managers that can say they picked one. However, that’s exactly what Firetrail Investments fund manager, Eleanor S...

It was a mixed bag of results for ASX healthcare shares as we walked through October, as some names came in red hot, whilst others missed the mark completely. After a sharp downturn in late September, where it lost around 7% in just one w...

After a positive start the ASX finished down over 0.5%. Today, APRA ordered the big banks to increase the home loan “serviceability buffer” from 2.5% to 3% from the end of October and hinted more regulation could be forthcoming. Also hittin...

The Aroa Biosurgery Ltd (ASX: ARX) share price is climbing in early trade this morning as the company released its preliminary half-year results. At the time of writing, the surgical technology company’s share price is up 14.81% from the...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

Earlier this week the Pinnacle Investment Summit was held and a number of ASX fund managers outlined the stocks they backed. One was Marcus Burns from Spheria Asset Management and he backed one of the ASX’s newest retailers.   Universal Sto...

The cavalcade of life science initial public offers (IPOs) and ASX listings shows few signs of receding, with BCAL Diagnostics (ASX:BDX) last week braving the bourse amid choppy global market conditions. In the life sciences IPO Olympiad, w...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date. Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain,...

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has announced the successful completion of a $47 million placement to institutional and sophisticated investors.

The ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of the bourse down with it. The ASX 200 retreated 0.7% to close at 7,379 points while the ASX Emerging Companies Index lost 1.06%, closing at 2...

The ASX 200 touched intraday record highs, but could not hold on and closed the day just shy of its all time high. The benchmark index finished 0.46% higher at 7,428, and is now on track to finish July on a 10-month winning streak. Six out...

The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

The Aroa Biosurgery Ltd (ASX: ARX) share price is on the move on Tuesday morning. At the time of writing, the soft-tissue regeneration company’s shares are up 1.5% to $1.20. Why is the Aroa Biosurgery share price rising? Investors have be...

The ASX picked up where it left off before the Easter break with another day of gains. The ASX 200 rose 0.84 per cent to 6,886 points and the ASX Emerging Companies Index rose 1.17 per cent, closing at 2,036 points. Utilities and energy wer...

The Aroa Biosurgery Ltd (ASX: ARX) share price is up 2.6% after the company shared positive news this morning. A new product from the soft-tissue regeneration company has received US Food and Drug Administration (FDA) clearance. At the tim...

Source: Monster Ztudio, Shutterstock Summary Allegra Orthopaedics has reported completing the 8-week timeline for the large animal pilot study for its Spinal Cage Device. Soft-tissue regeneration company Aroa Biosurgery has obtained F...

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has announced the US FDA has granted 510(k) clearance for its Myriad Morcells.

ASX mid-cap healthcare company Avita Medical Inc (ASX: AVH) released its second-quarter FY21 results to the market last week. Despite recording positive revenue numbers, the Avita share price has continued to slide lower over the last five...

Shares in ASX healthcare company Polynovo Limited (ASX: PNV) almost doubled in price last year. And, despite a shaky start to 2021, at their current price of $2.62 they are still up over 100% versus their March 2020 low of $1.275. For inve...

New ASX stocks are beating the old in 2020 and some experts are predicting that this will trigger an IPO revival this year. Initial public offering (IPO) platform OnMarket found that year-end IPOs outperformed the  S&P/ASX 200 Index (I...

Peter Switzer is joined by Brian Ward, the founder and CEO of soft tissue regeneration company Aroa (ARX).

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) says the Indian regulator has approved three of its products based on the ECM platform.

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) could be about to end its winning streak. The benchmark index is currently down 0.15% to 6,673.1 points. Four shares that have fallen more than most today are listed below. Here’s why...

Shares in soft tissue regeneration company, Aroa Biosurgery Ltd (ASX: ARX), are falling lower this morning after the company reported a 10% decline in revenue for the first half of FY21. At the time of writing, the Aroa Biosurgery share pr...

On Tuesday Pinnacle Investment Management Group Ltd (ASX: PNI) held its Pinnacle 2020 Virtual Summit, with a number of leading fund managers sharing their views on the small cap sector. Four small cap ASX shares that were picked out by fun...

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has provided an update it says highlights the recovery in its sales that were impacted by the COVID-19 pandemic in the June quarter. 

The sudden drop in spot gold prices and reintroduction of COVID-19 restrictions in New Zealand have hit the relevant ASX small caps this morning. After 100 days of being virus-free, four COVID-19 cases were detected in the country. New Zeal...

ASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020’s total above $30bn. According to Bloomberg, there has been $32.3bn worth of cash raised between January 1 and August 3. This is well ahead...

The Aroa Biosurgery Ltd (ASX: ARX) share price has closed 7.69% higher today after announcing it has secured United States Food and Drug Administration (FDA) clearance for one of its products, ‘Symphony’. In addition, the company received...

Shareholders in biological scaffold maker Aroa Biosurgery (ASX:ARX) got a double treat on Thursday morning after the company received both FDA and European regulator approvals. The Auckland headquartered company makes and sells products bas...

Newly-listed soft tissue regeneration company Aroa Biosurgery (ASX: ARX) has announced that its Symphony and Myriad complex wound healing products have gained clearance from international regulators. Symphony has received approval from the...

Aroa Biosurgery Ltd (ASX: ARX) knocked the lights out on its ASX opening day debut on Friday. The New Zealand-based medical company entered the Australian market on the final day of trading last week. It sold 40 million new shares at an in...